You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 18, 2025

Claims for Patent: 11,690,826

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,690,826

Title:	Methods for treating demodex blepharitis using lotilaner formulations
Abstract:	Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Inventor(s):	Bobak Robert Azamian, Douglas Michael Ackermann, Shawn D. Hickok, Joseph G. Vehige
Assignee:	Tarsus Pharmaceuticals Inc
Application Number:	US17/873,540
Patent Claims:	1. A method for treating Demodex blepharitis, comprising topically administering directly to an ocular surface of one or more eyes of a human patient in need of treatment thereof an effective amount of an ophthalmic composition, wherein the ophthalmic composition comprises lotilaner and a pharmaceutically acceptable vehicle, and wherein the lotilaner is present at about 0.25% by weight with respect to the total weight of the composition administered. 2. The method of claim 1, wherein the ophthalmic composition comprises an eye drop. 3. The method of claim 1, wherein topically administering further comprises topically administering the ophthalmic composition at least once daily for at least about 4 weeks. 4. The method of claim 3, wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient. 5. The method of claim 1, wherein topically administering further comprises topically administering the ophthalmic composition at least twice daily for at least about 6 weeks. 6. The method of claim 5, wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient. 7. The method of claim 1, wherein topically administering further comprises topically administering the ophthalmic composition at least twice daily for at least about 90 days. 8. The method of claim 7, wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient. 9. The method of claim 1, wherein topically administering further comprises topically administering the ophthalmic composition at least three times daily for at least about 90 days. 10. The method of claim 9, wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient. 11. A method for treating Meibomian gland dysfunction caused by Demodex infestation, comprising topically administering directly to one or more of the eye, eyelids, or eyelashes of a human patient in need of treatment thereof an effective amount of an ophthalmic composition, wherein the ophthalmic composition comprises lotilaner and a pharmaceutically acceptable vehicle, and wherein the lotilaner is present at about 0.25% by weight with respect to the total weight of the composition administered. 12. The method of claim 11, wherein the ophthalmic composition comprises an eye drop. 13. The method of claim 11, wherein topically administering further comprises topically administering the ophthalmic composition at least once daily for at least about 4 weeks. 14. The method of claim 13, wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient. 15. The method of claim 11, wherein topically administering further comprises topically administering the ophthalmic composition at least twice daily for at least about 6 weeks. 16. The method of claim 15, wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient. 17. The method of claim 11, wherein topically administering further comprises topically administering the ophthalmic composition at least twice daily for at least about 90 days. 18. The method of claim 17, wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient. 19. The method of claim 11, wherein topically administering further comprises topically administering the ophthalmic composition at least three times daily for at least about 90 days. 20. The method of claim 19, wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.